Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexchlorpheniramine + lorazepam
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of dexchlorpheniramine (an antihistamine) and lorazepam (a benzodiazepine). When used together, these medications can cause additive central nervous system depression, including increased drowsiness, dizziness, and confusion. The therapeutic efficacy of lorazepam may be decreased when used in combination with dexchlorpheniramine maleate.
02
Targets
GABRR (GABA-A receptor subunit rho)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on dexchlorpheniramine + lorazepam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexchlorpheniramine + lorazepam.